A fa­vorite in Alex­ion’s C-suite is leav­ing, and some mighty sur­prised an­a­lysts aren’t the least bit hap­py about ...

6 years ago
People

Benev­o­len­tAI draws $90M from Temasek amid re­ports of halved val­u­a­tion

6 years ago
Financing
AI

Af­ter tout­ing Gazy­va's po­ten­tial in lu­pus, Roche nabs 'break­through' ahead of PhI­II

6 years ago
Pharma

Pop­u­la­tion phar­ma­co­ki­net­ics: Drug­mak­ers seek clar­i­ty and ad­di­tions to re­vised FDA guid­ance

6 years ago
Pharma
FDA+

FDA col­lab­o­rates with Health Cana­da, Aus­tralia to ap­prove new can­cer drugs

6 years ago
FDA+

Pre­clin­i­cal can­cer biotech IGM Bio­sciences sets stage for up­sized $175M IPO

6 years ago
Financing
Startups

Mer­ck helps bankroll new part­ner Themis' game plan to fin­ish the chikun­gun­ya race and be­gin on­colyt­ic virus quest

6 years ago
Financing

Swiss biotech rais­es $16M to test 'un­de­liv­ery mech­a­nis­m' for rare liv­er dis­ease

6 years ago
Financing

Ex­plo­sion, fire rip Russ­ian re­search fa­cil­i­ty hous­ing small­pox, Ebo­la

6 years ago
Discovery

Last rites for Si­en­na, as strug­gling biotech files for Chap­ter 11

6 years ago
FDA+

Am­gen inks dis­cov­ery deal with Hum­ming­bird; Mer­ck gains pri­or­i­ty re­view for Ebo­la vac­cine

6 years ago
News Briefing

FDA ex­plains plans for new phar­ma­ceu­ti­cal qual­i­ty as­sess­ment sys­tem

6 years ago
FDA+

San Diego cou­ple charged with steal­ing trade se­crets, open­ing Chi­nese biotech as DOJ crack­down con­tin­ues

6 years ago
R&D
China

Scott Got­tlieb is once again join­ing a team that en­joyed good times at the FDA un­der his high-en­er­gy stint at the ...

6 years ago
People

Bio­gen pulls the plug on prized IPF drug from $562M+ Stromedix buy­out

6 years ago
R&D

Warts for the win: Aclar­is' lead drug clears piv­otal study

6 years ago
R&D

Could psy­che­delics tack­le the obe­si­ty cri­sis? A long­time re­searcher in the field says his lat­est mouse study sug­gests ...

6 years ago
R&D

Ac­celeron drops a de­vel­op­ment pro­gram as #2 drug fails to spark func­tion­al ben­e­fits in pa­tients with a rare ...

6 years ago
R&D

#UK­BIO19: Join GSK’s Hal Bar­ron and a group of top biotech ex­ecs for our 2nd an­nu­al biotech sum­mit in Lon­don

6 years ago
Bioregnum
Opinion

Scott Got­tlieb has a new board po­si­tion to add to the re­sume — and this one is fo­cused on a fa­vorite sub­ject

6 years ago
People
Pharma

As­traZeneca's di­a­betes drug grant­ed fast track des­ig­na­tion for heart fail­ure; Ver­ri­ca sends skin in­fec­tion treat­ment ...

6 years ago
News Briefing

Benev­o­len­tAI's lat­est fi­nanc­ing could halve its $2B val­u­a­tion — and that has Wood­ford watch­ers wor­ried

6 years ago
Financing
Startups

Seat­tle Ge­net­ics/Astel­las win pri­or­i­ty US re­view for armed an­ti­body aimed at blad­der can­cer

6 years ago
R&D
FDA+

Karyopharm lines up $150 mil­lion cash in­jec­tion to back con­tro­ver­sial drug launch

6 years ago
R&D
First page Previous page 912913914915916917918 Next page Last page
A service from the Financial Times